Tirzepatide (10 mg Vial)

This reference covers Tirzepatide (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Tirzepatide (10 mg Vial)

Synonyms/Alias: Tirzepatide

Purity: Specification by inquiry

Custom Peptide Support

  • Sequence, purity and scale confirmation
  • CoA and technical documentation requests
  • API, research and cosmetic peptide options
  • Distributor and institution quotation support

This reference covers Tirzepatide (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.

Quickstart

Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.

Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).

Easy measuring: At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Notes

Practical considerations for consistency and safety. Use new sterile insulin syringes; dispose in a sharps container [7]. Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation [8]. For multi‑injection doses, use different sites for each injection on the same day. Inject slowly; wait a few seconds before withdrawing the needle. Document weekly dose, date, and injection site to maintain consistency. Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them [1].

Single peptide protocol reference: Available for related research, development or formulation inquiry workflows.

Reconstitution and handling reference: Available for related research, development or formulation inquiry workflows.

Research-use documentation inquiry: Available for related research, development or formulation inquiry workflows.

Weeks 1–4
Weekly Dose (mg): 2.5 mg | Units (per injection) (mL): 50 units (0.50 mL) × 1 injection
Weeks 5–8
Weekly Dose (mg): 5 mg | Units (per injection) (mL): 100 units (1.0 mL) × 1 injection
Weeks 9–12
Weekly Dose (mg): 7.5 mg | Units (per injection) (mL): 75 units (0.75 mL) × 2 injections
Weeks 13–16
Weekly Dose (mg): 10 mg | Units (per injection) (mL): 100 units (1.0 mL) × 2 injections
Long-term Storage Conditions
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Shipping Condition
Shipping conditions by inquiry

Peptide Vials (Tirzepatide, 10 mg each): 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 3 vials

12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 6 vials

16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 10 vials

Insulin Syringes (U‑100, 1 mL): 8 weeks: 8 syringes (1/week)

12 weeks: 16 syringes (~1.3/week avg)

16 weeks: 24 syringes (~1.5/week avg)

Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution. 8 weeks (3 vials): 6 mL → 1 × 10 mL bottle

12 weeks (6 vials): 12 mL → 2 × 10 mL bottles

16 weeks (10 vials): 20 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each administration day. Per week: 2 swabs (1 injection day)

8 weeks: 16 swabs → recommend 1 × 100‑count box

12 weeks: 24 swabs → recommend 1 × 100‑count box

16 weeks: 32 swabs → recommend 1 × 100‑count box

Product Gallery

Quick Inquiry

Customer Support & Price Inquiry

Send product, purity, quantity, destination and documentation requirements. Quantai will follow up through WhatsApp or email.

Email: kongq687@gmail.com

WhatsAppMia WhatsApp Business QR code

Address: Huangpu District, Guangzhou, China